No Photo Available

Last Update

2016-09-02T00:00:00.000Z

This profile was last updated on .

Is this you? Claim your profile.

Wrong Dan Shochat?

Dr. Dan Shochat

Owner

Agama Inc. (Consultants)

Direct Phone: (650) ***-****       

Get ZoomInfo Grow

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

Agama Inc. (Consultants)

Background Information

Employment History

Agenix Limited

Consultant

KALOBIOS PHARMACEUTICALS INC

Development

Bexxar

Consulting Vice President of Development

Intellect Neurosciences Inc

Group Director, Product Research and Development

Immunomedics , Inc.

Director of Biotechnology Development

American Cyanamid Company

Senior Vice President and Chief Scientific Officer

Coulter Pharmaceutical , Inc.

Vice President of Pharmaceutical Development

Deltagen , Inc.

Visiting Lecturer and Adjunct Professor At the Chemistry Department

Rutgers University

Affiliations

Co-Founder
Celscia Therapeutics Inc.

Scientific Advisory Board Member
PROLOR Biotech , Inc.

Member of the Technical Advisory Committee To the Board of Directors
ANSTO Inc

Founder
Center for Molecular Medicine and Immunology

Associate Member
University of Medicine and Dentistry of New Jersey

Founder
Biotechnology Development Section

Scientific Advisory Board Member
Modigene Inc.

Scientific Advisory Board Member
Mindset BioPharmaceuticals Inc

Education

Bachelor of Science

biology

Hebrew University

Master in Science

physiology

Hebrew University

Ph.D.

Biochemistry

L.S.U. Medical School

Ph.D.

biochemistry

Louisiana State University Medical Center

Web References (30 Total References)


Life Sciences News Headlines - ADC Review / Journal of Antibody-drug Conjugates

adcreview.com [cached]

Intellect's program is led by Dan Shochat, Ph.D., Intellect Neurosciences' Consulting Vice President of Development and a pioneer in the development of antibody drug conjugates for cancer treatments.


About AMD :: Intellect Neurosciences, Inc

www.intellectns.com [cached]

IN-N01-OX2 development is being led by Dan Shochat, Ph.D., Consulting Vice President Development, an internationally recognized leader in the development of antibody products. Dr. Shochat led the development of Bexxar®, a radioiodinated antibody for the treatment of Non-Hodgkin's Lymphoma, which was approved by the FDA in June 2003. At American Cyanamide Co. and in collaboration with Celltech, Dr. Shochat led the development of the first approved antibody-drug conjugate, Mylotarg®. He also invented the technology and single-vial formulation and then developed the FDA-approved in vivo tumor-imaging reagent CEA-Scan®. With Dr. Shochat's expert assistance, Intellect has developed a detailed road-map for IN-N01-OX2 development to lead to the first clinical trials being initiated by the end of 2014.


David Pritchard | KaloBios Pharmaceuticals | Email CEO @kalobios.com CFO

www.lead411.com [cached]

Dan Shochat VP Non-clinical Development


Management Team :: Intellect Neurosciences, Inc

www.intellectns.com [cached]

Dan Shochat, Ph.D. Vice President

Dan Shochat, Ph.D. has more than 28 years of experience in the biotechnology industry and is a pioneer in the antibody development arena. Prior to joining Intellect, he served as vice president of nonclinical development at KaloBios Therapeutics. Prior, he was among the first employees of Immunomedics Inc., Newark, NJ where he served as group director, product R&D. Dr. Shochat is the inventor of several technologies, including that of the approved in vivo tumor-imaging agent CEA-Scan; Mylotarg - the first approved antibody-cytotoxic drug conjugate; and the design, process and formulation for the commercial radiolabeling of the B1 antibody at a 55 Curie scale. The lead product from this work was Bexxar, a radioiodinated antibody for the treatment of Non-Hodgkin's Lymphoma that was approved by the FDA on June 2003. He is co-founder of Celscia Therapeutics Inc. - a therapeutic antibodies development company - which merged with KaloBios Therapeutics in January 2004.
From 2001 to 2007 Dr. Shochat was a member of the Technical Advisory Committee to the Board of Directors of the Australian Nuclear Science and Technology Organization. He also serves as consultant and member of scientific advisory boards of several biopharmaceutical companies and venture capital funds.
Dr. Shochat earned B.Sc. in Zoology and Physiology (1965) and M.Sc. in Physiology (1968) from the Hebrew University of Jerusalem, Israel and Ph.D. in Biochemistry and Protein Chemistry (1976) from LSU Medical Center, New Orleans, LA. He was a post-doctoral fellow in the Department of Biochemistry (1975-1978) and Sr. Research Associate at the Division of Experimental Pathology (1978-1983), the University of Kentucky Medical Center, Lexington, KY. In 1983 he participated in founding the Center for Molecular Medicine and Immunology at the University of Medicine and Dentistry of New Jersey, Newark, NJ, where he was an Associate Member until he joint Immunomedics, Inc. in 1984. From 1986-1992 Dr. Shochat served successively as visiting lecturer and adjunct professor at the Chemistry Department of Rutgers University Graduate School (Newark, NJ campus).


News for Friday, 10 August 2012 - www.implu.com

www.implu.com [cached]

SHOCHAT DAN, a major shareholder at KALOBIOS PHARMACEUTICALS INC

Similar Profiles

Other People with this Name

Other people with the name Shochat

Hadar Shochat
MindU Ltd

Elisheva Shochat
Philips Hospital

Eddie Shochat
Amazon.com, Inc.

Eden Shochat
Tmura

Sharon Shochat
The Henry Jackson Society Inc

City Directory Icon

Browse ZoomInfo's Business Contact Directory by City

People Directory Icon

Browse ZoomInfo's
Business People Directory

Company Directory Icon

Browse ZoomInfo's
Advanced Company Directory